Tumor Necrosis Factor Inhibitors - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The tumor necrosis factor inhibitors market size is estimated at USD 42.57 billion in 2026, and is expected to reach USD 50.77 billion by 2031, at a CAGR of 3.59% during the forecast period (2026-2031). This report is Segmented by Drug Class (Adalimumab, and More), Indication (Rheumatoid Arthritis, Psoriatic Arthritis, and More), Formulation (Prefilled Syringe, and More), End-User (Hospital Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Tumor Necrosis Factor Inhibitors Market Trends and Insights

Increasing Global Prevalence of Autoimmune Disorders and Rise in Geriatric Population

Rheumatoid arthritis affects roughly 18 million people worldwide, and incidence climbs in populations older than 65, a cohort expanding faster than any other age group. Earlier imaging with ultrasound and MRI now detects subclinical inflammation, raising the treatment-eligible pool for psoriatic arthritis and ankylosing spondylitis by nearly 20% since 2024. Inflammatory bowel disease registries document double-digit growth in cases of Crohn’s disease and ulcerative colitis, partly attributed to lifestyle factors that alter the gut microbiota. This epidemiologic pressure sustains baseline demand even when unit prices fall. As a result, the tumor necrosis factor inhibitors market continues to widen its treated base, enabling manufacturers to preserve revenue streams despite biosimilar penetration.

Accelerated Biosimilar Approvals & New Product Launches

The FDA cleared eight adalimumab biosimilars through July 2023, with Cyltezo and Simlandi earning interchangeability status that permits pharmacy substitution. European tender systems are expected to drive infliximab biosimilar uptake above 90% in Denmark and Norway by 2024. Samsung Bioepis and Celltrion expanded their portfolios with copies of etanercept and infliximab, securing approvals in China, Japan, and India, while leveraging their domestic plants to lower the cost of goods. As patent cliffs approach for certolizumab pegol and golimumab, pipeline entrants aim to maintain the biosimilar price-volume flywheel. Collectively, these launches accelerate the shift toward lower-priced alternatives, reshaping formulary access across mature markets.

Severe Adverse Events & Safety Warnings

All TNF inhibitors carry boxed warnings for serious infections, with 2024 guidance emphasizing tuberculosis screening and vigilance for opportunistic pathogens. Pediatric malignancy alerts prompt mandatory cancer registries, boosting compliance costs for sponsors. Sporadic but fatal hepatosplenic T-cell lymphoma cases, especially among adolescent males on combination therapy, heighten prescriber caution. Safety monitoring elevates operational expenses and can delay treatment initiation, temporarily damping volume growth. Competing biologics with cleaner safety profiles, such as IL-23 inhibitors, capitalize on these concerns to gain market share in dermatology and rheumatology.

Other drivers and restraints analyzed in the detailed report include:

• Expanding Clinical Indications of TNF Inhibitors
• Favorable Reimbursement Policies in Developed Markets
• High Cost of Patented Biologics & Access Barriers

Segment Analysis

Adalimumab retained a 42.45% share of 2025 sales; however, the tumor necrosis factor inhibitors market share for this molecule is declining as eight U.S. biosimilars compete directly with it. Hyrimoz alone garnered a double-digit share within a year of its launch, as pharmacy benefit managers delisted Humira in favor of lower-cost options. The tumor necrosis factor inhibitors market now favors biosimilars that replicate proven efficacy while underpricing reference brands by as much as 55%. Etanercept and infliximab face similar pressure, with European tender systems mandating wholesale switching. Certolizumab pegol and golimumab occupy smaller yet more stable niches: one offers monthly dosing, while the other avoids placental transfer, making them appealing options for pregnant patients. Longer-acting TNF inhibitors in early pipelines may offset some erosion if they secure quarterly or twice-yearly dosing, but commercial timelines stretch beyond 2030.

Biosimilar volumes climb at a 5.43% CAGR, nearly double the class average, a dynamic that compresses revenue per dose yet broadens total patient reach. Originators are pivoting toward next-generation agents, such as Skyrizi and Rinvoq, to protect their profitability. Investors, therefore, judge incumbents more on the depth of their pipeline than on their ability to defend legacy franchises. For new entrants, manufacturing scale and device partnerships with firms like Ypsomed matter more than Salesforce's size. The path forward rewards low-cost producers and companies that pair molecules with digital adherence ecosystems.

Rheumatoid arthritis accounted for 28.54% of 2025 revenues, anchoring the largest patient population treated with TNF blockers. Yet ulcerative colitis posts the fastest trajectory, expanding at a 6.89% CAGR as boxed warnings constrain JAK inhibitor use and payers institute step-therapy that starts with TNF inhibition. The tumor necrosis factor inhibitors market size for gastroenterology indications is forecast to surpass USD 15 billion by 2031, making this specialty a priority for biosimilar marketers seeking large-volume contracts. Psoriatic arthritis and ankylosing spondylitis each benefit from earlier imaging-based diagnoses that extend biologic eligibility, while Crohn’s disease growth stabilizes at mid-single digits.

Hidradenitis suppurativa, although currently a niche condition, presents a high unmet need and a strong real-world response, allowing for premium pricing despite class-wide discounts. Pediatric trials, if successful, will unlock longer treatment durations per patient, as children initiating therapy may remain on TNF inhibitors through adolescence and early adulthood. Hence, sustained label expansion neutralizes some of the revenue loss from price pressure, keeping the tumor necrosis factor inhibitors market relevant across various specialties.

Complete Report Scope:

• By Drug Class
  • Adalimumab
  • Etanercept
  • Infliximab
  • Golimumab
  • Certolizumab Pegol
  • TNF-Inhibitor Biosimilars
  • Other Drug Classes
• By Indication
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Crohn's Disease
  • Ulcerative Colitis
  • Psoriasis
  • Hidradenitis Suppurativa
  • Other Indications
• By Formulation
  • Prefilled Syringe
  • Auto-Injector Pen
  • Lyophilized Powder / Vial
• By End-user
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest Of Asia-Pacific
  • Middle East And Africa
    • GCC
    • South Africa
    • Rest Of Middle East And Africa
  • South America
    • Brazil
    • Argentina
    • Rest Of South America

Geography Analysis

North America dominated spending with a 42.65% share in 2025, driven by Medicare policy that mandates the inclusion of biosimilars and caps co-pays, thereby directly stimulating volume. Private insurers widened the gap by excluding branded Humira from formularies, accelerating biosimilar uptake, and illustrating how payer policy overrides nominal list-price cuts. The tumor necrosis factor inhibitors market is shifting toward lower-cost options, even as total prescriptions increase, reflecting demographic realities and the broad clinical applicability of these treatments.

Europe follows as the second-largest region, where national tender systems drive aggressive price competition, resulting in infliximab biosimilar penetration exceeding 90% in several Scandinavian countries. Germany and France deploy value-based contracts that lock in multi-year supply at predetermined discounts, ensuring price stability while safeguarding continuity of care. The region also leads in the adoption of subcutaneous infliximab, thereby easing hospital burdens and creating additional room for home-based care models.

The Asia-Pacific region is forecast to post a 4.56% CAGR through 2031 as Samsung Bioepis and Celltrion scale their regional manufacturing capacity and secure approvals in China, India, and Japan, without having to clear the interchangeability hurdles that slow U.S. penetration. Local production lowers landed cost, allowing more aggressive tender bids. Emerging economies in Southeast Asia, however, remain constrained by fragmented reimbursement systems and uneven cold-chain infrastructure. Tiered pricing and public-private manufacturing deals will be critical to unlocking latent demand.

The Middle East, Africa, and South America collectively trail due to affordability limits, high out-of-pocket costs, and weak distribution networks, keeping utilization confined mainly to urban private hospitals. Biosimilar discounts alone have not closed the access gap. Strategic partnerships with domestic pharmaceutical companies and regional logistics providers could help narrow disparities, but political and currency risks temper investment enthusiasm.

List of Companies Covered in this Report:

• Abbvie
• Amgen
• Boehringer Ingelheim
• Zydus Group
• Celltrion Healthcare Co Ltd
• Coherus BioSciences Inc
• Johnson & Johnson
• Lupin
• Novartis
• Pfizer
• Samsung Bioepis Co Ltd
• Sun Pharmaceuticals Industries
• UCB
• Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support